IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
cines with out this ad di tive de signed to in crease ef fi cacy. In Jan u ary 2009 Novartis was awarded a $486
mil lion grant from the US fed eral agency the HHS to fund a new pan demic flu vac cine man u fac tur ing fa cil -
ity. The HHS will pro vide money over eight years to sup port de sign, con struc tion, val i da tion and li cens ing
of the fa cil ity which will make cell-based vac cines. Novartis will pro vide a pre-pan demic sup ply of vac cine
and en sure ca pac ity to man u fac ture 150 million doses within six months of the declaration of a pandemic.
Novartis and Intercell es tab lished an al li ance in July 2007 that broad ens Novartis’ vac cines port fo lio.
Novartis has gained ac cess to over 10 Intercell pro jects in pre clin i cal and early-stage de vel op ment, in -
clud ing vac cines for pre ven tion of hos pi tal-ac quired in fec tions and other life-threat en ing dis eases, in re -
turn for an upfront pay ment and eq uity in vest ment to tal ing $364 mil lion. Novartis will as sume
re spon si bil ity for phase III de vel op ment, man u fac tur ing and com mer cial iza tion for any Intercell projects
chosen after phase II trials.
In 2008 Novartis cre ated a new busi ness unit within Pharmaceuticals, Novartis Mo lec u lar Di ag nos tics, to
lead new ini tia tives in med i cine-re lated di ag nos tics.
© 2009 IMS Health In cor po rated or its af fil i ates Page 73